Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Zipalertinib by Taiho Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Zipalertinib is under clinical development by Taiho Pharmaceutical and currently in Phase III for Non-Small Cell Lung Cancer. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Otsuka's Zipalertinib?
Zipalertinib is a small molecule commercialized by Otsuka, with a leading Phase III program in Non-Small Cell Lung Cancer. According...